Skip to main content

Lynparza 50mg capsules | Olaparib | Millionpharma

                                   LYNPARZA 50MG


DESCRIPTION


Olaparib is a generic form of brand name Lynparza 50 mg. Which is required for some types of ovarian cancer that have come back after treatment. It is for people whohave a alter in a gene called BRCA and have had a variety of chemotherapy called platinum Lynparza 50 mg which used asprescription drug which used under the supervision of medical practioners

Lynparza 50 mg Capsule
Lynparza 50 mg

INDICATION:

Lynparza 50 mg tablet is an antitumor medication which is
Indicated for the treatment in patients with advanced ovarian cancer
Indicated for the treatment in patients with HER2 – negative metastatic breast cancer.


MECHANISM OF ACTION:


Olaparib belongs to poly (ADP-ribose) polymerase (PARP) enzyme inhibitor, containing PARP1, PARP2, and PARP3. PARP enzymes are included in DNA transcription, cell cycle managing, and DNA repair.
Olaparib consist of anefficient oral PARP inhibitor thatactivates synthetic lethality in BRCA1/2 deficient cancer cells via the formation of double-stranded DNA breaks that cannot be exactly repaired, which causesinterruption of cellular homeostasis and cell death




ADME


High plasma concentration 1 to 3 hours
plasma protein binding is 82%
Volume of distribution 167 +/-196 L
Primarily metabolised by CYP3A4
Excreted via urine 44% and 42% through the feces.
Lynparza 50 mg Half – life is 11.9 hours

Ovarian cancer :

Maintenance treatment of relapsed ovarian cancer
The tablet prescribed dose is 300mg (two 150mg – mg tablets) PO BID
Follow treatment until disease progression or unacceptable toxicity
Single treatment for advanced BRCA – mutated ovarian cancer
The tablet prescribed dose is 300mg (two 150mg – mg tablets) PO BID
The capsules recommended dose is 400mg (eight 50mg- mg capsules) PO BID
Follow treatment until disease progression or unacceptable toxicity.
Support treatment for advanced BRCA-mutated ovarian cancer
The tablet prescribed dose is 300mg administer two 150mg – mg tablets PO BID
Continue the therapy until disease progression, undesirable toxicity or completion of 2 years of treatment
Finishing of 2 years of treatment :
• Full response of drug to patients (no radiologic evidence): discontinue treatment
• Patients with symptoms of disease and may asset from continuous treatment treat beyond 2 years.

While on therapy with drug will cause Haematological toxicity in patientsincluding diagnoses or findings of commonly mild or moderate anaemia, neutropenia, thrombocytopenia and lymphopenia.
Monotherapy administration of Lynparza 50 mg to patient the incidence of myelodysplastic syndrome will occur.
On basis of mechanism of action (PARP inhibition), Lynparza 50 mg tablet could cause fetal harm when administered to a pregnant woman.
Lynparza 50 mg concomitant use with strong or moderate CYP3A inhibitors is not recommended.

Common side effects for patients taking Olaparib :

• Musculoskeletal pain
• Diarrhea
• Decreased platelet count
• Decreased Haemoglobin
• Nausea
• Decreased white blood cell count
• Abdominal pain
• Vomiting
• Upper respiratory tract infection
• Anemia
• Decreased neutrophils
• Fatigue (including weakness)
• Increased serum creatinine

Less common side effects of patients administrating Olaparib :

• Vertigo
• Constipation
• Urinary tract infection
• Heartburn
• Decreased appetite
• Shortness of breath
• Myalgia
• Headache
• Skin rash
• Back pain
• Taste changes
• Cough
• Swelling

Contact us       :+91-9940472902
Email      : millionhealthpharmaceuticals@gmail.com
Labels:

Comments

Post a Comment

Popular posts from this blog

Stivarga 40mg Tablets| Regorafenib Uses & Side effects

STIVARGA 40MG DESCRIPTION Stivarga 40mg consist of protein kinase inhibitor with a similar structure to sorafenib. It is hoping to act by prohibiting multiple signalling pathways contains in angiogenesis and tumour growth. Stivarga 40mg is commonly given after other chemotherapy have been tried without success. Stivarga 40mg which is used as prescription drugs under the supervision of medical practioners. INDICATION: Stivarga 40mg is an anticancer drug which is; Indicated for the treatment of Hepatocellular carcinoma Indicated for the treatment of Colorectal cancer Indicated for the treatment of Gastrointestinal stromal tumor MECHANISM OF ACTION: Regorafenib consist of systemic therapy which works throughout your body to promote fight certain cancers. Regorafenib belongs to a multikinase inhibitor, may work by stopping some proteins on certain normal and cancer cells. In this way, Regorafenib may inhibit cancers from growing and spreading for a period. Can...
Post a Comment
Read more

Tagrisso 40mg Tablets| Osimeritinib Uses & Side effects

                                                   TAGRISSO 40MG DESCRIPTION A Tagrisso 40mg tablet is containing an active substance known as Osimeritinib, which is formerly known as Mereletinib. Tagrisso 40mg is considered as third generation medicine, which is available in tablet form. Tagrisso 40mg tablet is an inevitable, selectively deviated epidermal growth factor receptor prohibitor, containing anti-cancer activity. The pharmacological category of Tagrisso 40mg is tyrosine kinase prohibitor. INDICATION: A T agrisso 40mg tablet is widely indicated as first line therapy for advanced non-small cell lung cancer with EGFR mutation positive patients.Tagrisso 40mg is also used for the treatment of patients affected with advanced EGFR T792M mutation positive NSCLC, disease has advanced on or after the tyrosine kinase inhibitor treatment. M...
Post a Comment
Read more